Eurax

Manufacturer
Journey Medical Corporation | DPT Laboratories, Ltd
Effective date
2025-12-17
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-05-31 22:09:40

Label at a glance#

ProductEurax
Active ingredientCROTAMITON
Label structure11 sections

Indications and uses

For eradication of scabies ( Sarcoptes scabiei ) and for symptomatic treatment of pruritic skin.

Dosage and administration

In Scabies: Thoroughly massage into the skin of the whole body from the chin down, paying particular attention to all folds and creases. A second application is advisable 24 hours later. Change clothing and bed linen the next morning. Take a cleansing bath 48 hours after the last application. In Pruritus: Massage gently into affected areas until medication is completely absorbed. Repeat as needed. Take a routine b...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Eurax (crotamiton, USP) is a scabicidal and antipruritic agent available as a cream for topical use only. Eurax provides 10% (w/w) of the synthetic, crotamiton, USP, in a vanishing-cream base containing: carbomer homopolymer type B, cetyl alcohol, diazolidinyl urea, dimethicone, glyceryl monostearate, laureth-23, magnesium aluminum silicate, benzyl alcohol, petrolatum, propylene glycol, sodium hydroxide, steareth-2, and water. Crotamiton is N-ethyl-N-( o-methylphenyl)-2-butenamide and its structural formula is:

structurenewstructurenew

Crotamiton, USP is a colorless to slightly yellowish oil, having a faint amine-like odor. It is soluble with alcohol and with methanol. Crotamiton is a mixture of the cisand transisomers. Its molecular weight is 203.28.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Eurax has scabicidal and antipruritic actions. The mechanisms of these actions are not known. The pharmacokinetics of crotamiton and its degree of systemic absorption following topical application have not been determined.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For eradication of scabies ( Sarcoptes scabiei) and for symptomatic treatment of pruritic skin.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Do not apply Eurax topically to patients who develop a sensitivity or are allergic to it or who manifest a primary irritation response to topical medications.

WARNINGS

WARNINGS SECTION

Discontinue treatment with this product if severe irritation or sensitization develops, and institute appropriate therapy.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Do not apply Eurax in the eyes or mouth because it may cause irritation. Do not apply on acutely inflamed skin or raw or weeping surfaces until the acute inflammation has subsided.

Information for Patients

INFORMATION FOR PATIENTS SECTION

See DIRECTIONS FOR PATIENTS WITH SCABIES.

Drug Interactions

DRUG INTERACTIONS SECTION

None known.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term carcinogenicity studies in animals have not been conducted.

Pregnancy

PREGNANCY SECTION

Animal reproduction studies have not been conducted with Eurax. It is also not known whether Eurax can cause fetal harm when applied topically to a pregnant woman or can affect reproduction capacity. Eurax should be given to a pregnant woman only if clearly needed.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

GERIATRIC USE SECTION

Clinical studies with Eurax (crotamiton, USP) Cream did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Primary irritation reactions, such as dermatitis, pruritus, and rash, and allergic sensitivity reactions have been reported in a few patients.

OVERDOSAGE

OVERDOSAGE SECTION

There is no specific information on the effect of overtreatment with repeated topical applications in humans.
A death was reported but cause was not confirmed.
Accidental oral ingestion may be accompanied by burning sensation in the mouth, irritation of the buccal, esophageal and gastric mucosa, nausea, vomiting, abdominal pain.
If accidental ingestion occurs, call your Poison Control Center.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

In Scabies:Thoroughly massage into the skin of the whole body from the chin down, paying particular attention to all folds and creases. A second application is advisable 24 hours later. Change clothing and bed linen the next morning. Take a cleansing bath 48 hours after the last application.

In Pruritus:Massage gently into affected areas until medication is completely absorbed. Repeat as needed.

DIRECTIONS FOR PATIENTS WITH SCABIES:

INSTRUCTIONS FOR USE SECTION

  1. Take a routine bath or shower. Thoroughly massage Eurax cream into the skin from the chin to the toes including folds and creases.
  2. Put Eurax cream under fingernails after trimming the fingernails short, because scabies are very likely to remain there. A toothbrush can be used to apply the Eurax cream under the fingernails. Immediately after use, wrap the toothbrush in paper and throw it away. Use of the same brush in the mouth could lead to poisoning.
  3. A second application is advisable 24 hours later.
  4. A 60 gram tube is sufficient for two applications.
  5. Change clothing and bed linen the next day. Dry clean contaminated clothing and bed linen, or wash in the hot cycle of the washing machine.
  6. Take a cleansing bath 48 hours after the last application.

HOW SUPPLIED

HOW SUPPLIED SECTION

Eurax ®(crotamiton, USP) Cream, 10% is a white to yellowish-white soft cream and supplied as:
60 g tube                 NDC 69489-311-60

Store at room temperature, 20˚C - 25˚C (68˚F - 77˚F); Excursions permitted: 15˚C - 30˚C (59˚F - 86˚F)
[See USP Controlled Room Temperature].

Keep out of reach of children.

To report SUSPECTED ADVERSE REACTIONS, contact Journey Medical Corporation at 1-855-531-1859 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

logologo

Manufactured for:
Journey Medical Corporation
Scottsdale, AZ 85258
www.JMCderm.com

EUR-P01-R00                                                                                                                            Revised 12/2025

PACKAGE LABEL PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 69489-311-60

eurax ®

(crotamiton, USP) Cream (10% w/w)

Rx Only

For topical use only.
Not for ophthalmic, oral,
or intravaginal use.

Net Wt. 60 g

tubelabeltubelabel

NDC 69489-311-60

eurax ®

(crotamiton, USP) Cream (10% w/w)

Rx Only

For topical use only.
Not for ophthalmic, oral,
or intravaginal use.

Net Wt. 60 g

creamcartonlabelcreamcartonlabel

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
309552crotamiton 10 % Topical CreamPSN2
207864Eurax 10 % Topical CreamPSN2
207864crotamiton 100 MG/ML Topical Cream [Eurax]SBD2
309552crotamiton 100 MG/ML Topical CreamSCD2
309552crotamiton 10 % Topical CreamSY2
207864Eurax 10 % Topical CreamSY2

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
2ea7942c-f3b4-4c60-49a3-bfc71c3c134eProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
69489-311-60Eurax60 g in 1 TUBECREAM602
69489-311-60Eurax1 in 1 CARTONCREAM12

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 15 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
69489-31169489-311-60

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 14 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N006927-001EURAXCROTAMITON10%CREAM / TOPICALRLD, RS, Approved before 1982

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N006927-001EURAX10%CREAM / TOPICALRLD, RS, Approved before 198284e616aacf4f…
2026-08-18 06:07:402026-07N006927-001EURAX10%CREAM / TOPICALRLD, RS, Approved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 1982301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19821e350fbaab3a…
2024-05-31 18:47 UTC2024-05N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19828072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19825c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19825d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19824b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 198274a2ff9319b5…
2022-03-09 01:35 UTC2022-03N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 1982bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 1982782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 198287673890dc5c…
2021-03-12 10:30 UTC2021-03N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19825aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19828869cabd3fbd…
2020-11-12 02:37 UTC2020-11N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 1982c0c555d07b60…
2019-12-14 00:12 UTC2019-12N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19823f01610625f2…
2019-09-15 20:21 UTC2019-09N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 1982b00525d2431f…
2019-07-19 19:46 UTC2019-07N006927-001EURAX10%CREAM / TOPICALRLD, RS, Approved before 1982ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19826a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19821c564ffb4f44…
2023-12-20 04:57 UTC2023-12N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 1982ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 1982a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19829b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 1982a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19823f0d92c62455…
2023-05-13 08:27 UTC2023-05N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 1982053a50430f4f…
2023-01-26 05:58 UTC2023-01N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19823bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 19823a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N006927-001EURAX10%CREAM / TOPICALRLD, Approved before 1982f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
EuraxCROTAMITONJourney Medical Corporation99c826aa-c7dd-4e60-be9c-e9c151033d132025-12-17Warnings, Adverse reactionsExact identifier
ndc (package): 69489-311-60
ndc (product): 69489-311
ndc11 (package): 69489031160
spl id: 4640ba32-cf20-18ad-e063-6394a90a4592
spl set id: 99c826aa-c7dd-4e60-be9c-e9c151033d13

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.